日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Correction to: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program

更正：ALLEGRO临床试验项目中口服JAK3/TEC家族激酶抑制剂Ritlecitinib治疗斑秃的综合安全性分析

期刊:American Journal of Clinical Dermatology
影响因子:8.8
doi:10.1007/s40257-025-00976-2
King, Brett; Soung, Jennifer; Tziotzios, Christos; Rudnicka, Lidia; Joly, Pascal; Gooderham, Melinda; Sinclair, Rodney; Mesinkovska, Natasha A; Paul, Carle; Gong, Yankun; Anway, Susan D; Tran, Helen; Wolk, Robert; Zwillich, Samuel H; Lejeune, Alexandre
JAK/STAT
信号转导
TEC
JAK3
发表日期：2025
文献求助 收藏

Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme

在ALLEGRO临床开发项目中，接受利特西替尼治疗的斑秃患者的临床反应模式

期刊:Journal of the European Academy of Dermatology and Venereology
影响因子:8
doi:10.1111/jdv.20547
King, B; Mirmirani, P; Lo Sicco, K; Ramot, Y; Sinclair, R; Asfour, L; Ezzedine, K; Paul, C; Ohyama, M; Edwards, R A; Bonfanti, G; Kerkmann, U; Wajsbrot, D; Ishowo-Adejumo, R; Zwillich, S H; Lejeune, A
发表日期：2025
文献求助 收藏

Rates of Infections, Malignancies, Cardiovascular Outcomes, and Death in Individuals with Hospital-treated Alopecia Areata: A Registry-based Cohort Study in Denmark

丹麦一项基于登记数据的队列研究：接受医院治疗的斑秃患者的感染率、恶性肿瘤发生率、心血管事件发生率和死亡率

期刊:Acta Dermato-Venereologica
影响因子:3.7
doi:10.2340/actadv.v105.42646
Sørensen, Sissel Brandt Toft; George, Prethibha; Jagun, Oladayo; Wolk, Robert; Napatalung, Lynne; Zwillich, Samuel H; Iversen, Lars; Ehrenstein, Vera
炎症/感染
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Using patient preference to inform ritlecitinib dose selection for alopecia areata treatment

利用患者意愿指导利妥昔单抗治疗斑秃的剂量选择

期刊:Journal of Dermatology
影响因子:2.7
doi:10.1111/1346-8138.17628
Hauber, Brett; Whichello, Chiara; Mauer, Jonathan; Law, Ernest; Trapali, Myrto; Whalen, Edward; Wajsbrot, Dalia; Krucien, Nicolas; Tervonen, Tommi; Zwillich, Samuel H; Wolk, Robert
发表日期：2025
文献求助 收藏

Patient satisfaction with hair regrowth in a study of ritlecitinib: a plain language summary

利特西替尼研究中患者对毛发再生的满意度：简明语言总结

期刊:Immunotherapy
影响因子:2.3
doi:10.1080/1750743X.2025.2513849
Sinclair, Rodney; Law, Ernest H; Zhang, Xingqi; Zhang, Fan; Napatalung, Lynne; Zwillich, Samuel H; King, Brett; Mesinkovska, Natasha
发表日期：2025
文献求助 收藏

A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areata

一项 2a 期研究，旨在调查利特西替尼对斑秃成人患者脑干听觉诱发电位和表皮内神经纤维组织学的影响

期刊:Pharmacology Research & Perspectives
影响因子:2.3
doi:10.1002/prp2.1204
Anderson, Samira; Cavaletti, Guido; Hood, Linda J; Polydefkis, Michael; Herrmann, David N; Rance, Gary; King, Brett; McMichael, Amy J; Senna, Maryanne M; Kim, Brian S; Napatalung, Lynne; Wolk, Robert; Zwillich, Samuel H; Schaefer, Gregor; Gong, Yankun; Sisson, Melanie; Posner, Holly B
神经科学
发表日期：2024
文献求助 收藏

Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program

ALLEGRO 临床试验项目中口服 JAK3/TEC 家族激酶抑制剂 Ritlecitinib 治疗斑秃的综合安全性分析

期刊:American Journal of Clinical Dermatology
影响因子:
doi:10.1007/s40257-024-00846-3
Brett King, Jennifer Soung, Christos Tziotzios, Lidia Rudnicka, Pascal Joly, Melinda Gooderham, Rodney Sinclair, Natasha A Mesinkovska, Carle Paul, Yankun Gong, Susan D Anway, Helen Tran, Robert Wolk, Samuel H Zwillich, Alexandre Lejeune2
信号转导
JAK/STAT
发表日期：2024
文献求助 收藏

Incidence Rates of Infections, Malignancies, Thromboembolism, and Cardiovascular Events in an Alopecia Areata Cohort from a US Claims Database

美国医疗保险数据库中斑秃患者队列的感染、恶性肿瘤、血栓栓塞和心血管事件发生率

期刊:Dermatology and Therapy
影响因子:4.2
doi:10.1007/s13555-023-00937-9
George, Prethibha; Jagun, Oladayo; Liu, Qing; Wentworth, Charles; Napatalung, Lynne; Wolk, Robert; Anway, Susan; Zwillich, Samuel H
心血管
炎症/感染
肿瘤
肿瘤免疫
发表日期：2023
文献求助 收藏

Tofacitinib in Rheumatoid Arthritis: Lack of Early Change in Disease Activity and the Probability of Achieving Low Disease Activity at Month 6

托法替尼治疗类风湿性关节炎：早期疾病活动度未见明显改善以及6个月时达到低疾病活动度的概率

期刊:Arthritis Care & Research
影响因子:3.3
doi:10.1002/acr.23585
van Vollenhoven, Ronald F; Lee, Eun Bong; Fallon, Lara; Zwillich, Samuel H; Wilkinson, Bethanie; Chapman, Douglass; DeMasi, Ryan; Keystone, Edward
关节炎
发表日期：2019
文献求助 收藏

Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria

简报：托法替尼治疗类风湿性关节炎的缓解率：不同缓解标准的比较

期刊:Arthritis & Rheumatology
影响因子:10.9
doi:10.1002/art.39996
Smolen, Josef S; Aletaha, Daniel; Gruben, David; Zwillich, Samuel H; Krishnaswami, Sriram; Mebus, Charles
关节炎
发表日期：2017
文献求助 收藏